STOCK TITAN

Neumora (NASDAQ: NMRA) exec sells 277,773 shares near $1.5

(Very High)
(Negative)
Form Type
4

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) reported insider transactions by Chief Operating and Development Officer Aurora Daljit Singh over August 17–19, 2026. Singh exercised stock options at an exercise price of $0.72 per share for a total of 243,753 shares of common stock and reported 277,773 shares sold in open-market transactions at weighted average prices within ranges running from about $1.46 to $1.70 per share. Some transactions involved shares held indirectly through the Aurora Family Trust, whose beneficiaries are members of Singh’s immediate family.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider Aurora Daljit Singh
Role See Remarks
Sold 277,773 shs ($432K)
Approx. gross sale proceeds $432K
Approx. exercise cost $176K
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) F7 13,268 $0.00 $0.00
Exercise Stock Option (Right to Buy) F13 17,732 $0.00 $0.00
Exercise Stock Option (Right to Buy) F5, F3 30,918 $0.00 $0.00
Exercise Common Stock 13,268 $0.72 $10K
Exercise Common Stock 17,732 $0.72 $13K
Sale Common Stock F11 31,000 $1.6461 $51K
Exercise Common Stock F3 30,918 $0.72 $22K
Sale Common Stock F12, F3 30,918 $1.6459 $51K
Exercise Stock Option (Right to Buy) F7 34,162 $0.00 $0.00
Exercise Stock Option (Right to Buy) F5, F3 34,987 $0.00 $0.00
Exercise Common Stock 34,162 $0.72 $25K
Sale Common Stock F9 34,162 $1.5847 $54K
Exercise Common Stock F3 34,987 $0.72 $25K
Sale Common Stock F10, F3 34,987 $1.5859 $55K
Exercise Stock Option (Right to Buy) F5 40,890 $0.00 $0.00
Exercise Stock Option (Right to Buy) F6 15,355 $0.00 $0.00
Exercise Stock Option (Right to Buy) F7 1,424 $0.00 $0.00
Exercise Stock Option (Right to Buy) F8 1 $0.00 $0.00
Exercise Stock Option (Right to Buy) F5, F3 25,279 $0.00 $0.00
Exercise Stock Option (Right to Buy) F5, F3 29,737 $0.00 $0.00
Exercise Common Stock 40,890 $0.72 $29K
Exercise Common Stock 15,355 $0.72 $11K
Exercise Common Stock 1,424 $0.72 $1K
Exercise Common Stock 1 $0.72 $0.72
Sale Common Stock F1 57,670 $1.5055 $87K
Sale Common Stock F2 34,020 $1.4853 $51K
Exercise Common Stock F3 25,279 $0.72 $18K
Exercise Common Stock F3 29,737 $0.72 $21K
Sale Common Stock F4, F3 55,016 $1.5047 $83K
Holdings After Transaction: Stock Option (Right to Buy) — 1,393,180 shares (Direct); Stock Option (Right to Buy) — 45,026 shares (Indirect, See footnote); Common Stock — 48,750 shares (Direct); Common Stock — 0 shares (Indirect, See footnote)
Footnotes (13)
  1. F1. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  2. F2. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  3. F3. Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
  4. F4. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  5. F5. The stock option is fully vested and exercisable.
  6. F6. 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  7. F7. 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  8. F8. 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
  9. F9. This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  10. F10. This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  11. F11. This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  12. F12. This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
  13. F13. 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Total shares sold 277,773 shares Aggregate open-market sales reported in transactionSummary
Total shares from option exercises 243,753 shares Aggregate derivative exercises (M) reported in transactionSummary
Option exercise price $0.72 per share Conversion or exercise price for stock options exercised
Direct sale example price $1.5055 per share Weighted average price for 57,670-share direct sale on 2026-08-17
Indirect sale example price $1.5047 per share Weighted average price for 55,016-share indirect sale on 2026-08-17
Number of sale transactions 7 Non-derivative transactions coded S in transactionSummary
Number of option exercises 11 Derivative transactions coded M in transactionSummary
stock option financial
"The security title is listed as "Stock Option (Right to Buy)" in several rows"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
weighted average sale price financial
"Footnotes state the price reflects the weighted average sale price for multiple trades"
indirect ownership financial
"Certain transactions show ownership type as indirect with nature "See footnote""
Aurora Family Trust financial
"A footnote explains shares held by Aurora Family Trust for immediate family beneficiaries"
vesting commencement date financial
"Footnotes describe options vesting based on a specified Vesting Commencement Date"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

FAQ

What insider activity did NMRA report for Aurora Daljit Singh on this Form 4?

Aurora Daljit Singh reported mixed activity, exercising stock options and selling common shares. From August 17–19, 2026, Singh exercised options into 243,753 NMRA shares and reported open-market sales totaling 277,773 shares at weighted average prices within stated ranges.

How many NMRA shares did Aurora Daljit Singh sell according to this Form 4?

The filing reports open-market sales totaling 277,773 shares of Neumora Therapeutics common stock. These sales occurred over August 17–19, 2026, in multiple trades at weighted average prices within ranges generally between about $1.46 and $1.70 per share.

How many NMRA stock options did Aurora Daljit Singh exercise and at what price?

Aurora Daljit Singh exercised options covering 243,753 NMRA shares at an exercise price of $0.72 per share. These exercises, coded as derivative transactions (M), converted stock options into common stock over the three trading days reported in the Form 4.

Were any of Aurora Daljit Singh’s NMRA transactions made through a trust?

Yes. Some transactions involve shares held by the Aurora Family Trust. A footnote states that members of Singh’s immediate family are the sole beneficiaries of this trust, and certain option exercises and share sales are reported as indirect ownership through it.

What price ranges did NMRA insider share sales occur at in this filing?

Reported NMRA sales occurred in multiple trades within ranges from about $1.46 up to about $1.70 per share. The Form 4 notes that the per-share figures shown are weighted average sale prices for trades executed within those specified ranges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Aurora Daljit Singh

(Last)(First)(Middle)
C/O NEUMORA THERAPEUTICS, INC.
260 ARSENAL PLACE, SUITE 1

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/17/2026M40,890A$0.72123,660D
Common Stock08/17/2026M15,355A$0.72139,015D
Common Stock08/17/2026M1,424A$0.72140,439D
Common Stock08/17/2026M1A$0.72140,440D
Common Stock08/17/2026S57,670D$1.5055(1)82,770D
Common Stock08/17/2026S34,020D$1.4853(2)48,750D
Common Stock08/17/2026M25,279A$0.7225,279ISee footnote(3)
Common Stock08/17/2026M29,737A$0.7255,016ISee footnote(3)
Common Stock08/17/2026S55,016D$1.5047(4)0ISee footnote(3)
Common Stock08/18/2026M34,162A$0.7282,912D
Common Stock08/18/2026S34,162D$1.5847(9)48,750D
Common Stock08/18/2026M34,987A$0.7234,987ISee footnote(3)
Common Stock08/18/2026S34,987D$1.5859(10)0ISee footnote(3)
Common Stock08/19/2026M13,268A$0.7262,018D
Common Stock08/19/2026M17,732A$0.7279,750D
Common Stock08/19/2026S31,000D$1.6461(11)48,750D
Common Stock08/19/2026M30,918A$0.7230,918ISee footnote(3)
Common Stock08/19/2026S30,918D$1.6459(12)0ISee footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$0.7208/17/2026M40,890 (5)09/20/2031Common Stock40,890$00D
Stock Option (Right to Buy)$0.7208/17/2026M15,355 (6)01/19/2033Common Stock15,355$0192,546D
Stock Option (Right to Buy)$0.7208/17/2026M1,424 (7)06/23/2033Common Stock1,424$070,797D
Stock Option (Right to Buy)$0.7208/17/2026M1 (8)02/13/2035Common Stock1$0999,999D
Stock Option (Right to Buy)$0.7208/17/2026M25,279 (5)01/19/2033Common Stock25,279$0110,931ISee footnote(3)
Stock Option (Right to Buy)$0.7208/17/2026M29,737 (5)06/23/2033Common Stock29,737$00ISee footnote(3)
Stock Option (Right to Buy)$0.7208/18/2026M34,162 (7)06/23/2033Common Stock34,162$036,635D
Stock Option (Right to Buy)$0.7208/18/2026M34,987 (5)01/19/2033Common Stock34,987$075,944ISee footnote(3)
Stock Option (Right to Buy)$0.7208/19/2026M13,268 (7)06/23/2033Common Stock13,268$023,367D
Stock Option (Right to Buy)$0.7208/19/2026M17,732 (13)02/14/2034Common Stock17,732$0177,268D
Stock Option (Right to Buy)$0.7208/19/2026M30,918 (5)01/19/2033Common Stock30,918$045,026ISee footnote(3)
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
2. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.5277, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Shares held by Aurora Family Trust, of which members of the Reporting Person's immediate family are the sole beneficiaries.
4. This transaction was executed in multiple trades at prices ranging from $1.46 to $1.555, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
5. The stock option is fully vested and exercisable.
6. 25% of the shares subject to the option vest on the first anniversary measured from February 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
7. 25% of the shares subject to the option vest on the first anniversary measured from June 30, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
8. 25% of the shares subject to the option vest on the first anniversary measured from February 13, 2025 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
9. This transaction was executed in multiple trades at prices ranging from $1.49 to $1.645, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
10. This transaction was executed in multiple trades at prices ranging from $1.48 to $1.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
11. This transaction was executed in multiple trades at prices ranging from $1.62 to $1.6995, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
12. This transaction was executed in multiple trades at prices ranging from $1.62 to $1.7006, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
13. 25% of the shares subject to the option vest on the first anniversary measured from February 14, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.
Remarks:
Title: Chief Operating and Development Officer
/s/ Michael Milligan, as Attorney-in-Fact for Daljit Singh Aurora08/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)